Side-by-side comparison of AI visibility scores, market position, and capabilities
Global #1 OTC acetaminophen brand owned by Kenvue (NYSE: KVUE, J&J 2023 spinoff at $41B); Kimberly-Clark $48.7B Kenvue acquisition pending close H2 2026 competing with Advil and store brand for OTC pain relief market.
Tylenol is a global over-the-counter acetaminophen (paracetamol) pain relief and fever reducer brand — owned by Kenvue (NYSE: KVUE), the consumer health company spun off from Johnson & Johnson in May 2023 at a $41 billion IPO valuation, and subject to a pending $48.7 billion acquisition by Kimberly-Clark announced in November 2025 (expected to close second half 2026) — providing consumers with the world's most widely used analgesic through product lines including Tylenol Extra Strength, Tylenol PM, Tylenol Rapid Release Gels, Tylenol Children's, and Tylenol Arthritis Pain for adults and pediatric pain and fever management. Generating approximately $2 billion in annual retail sales as one of Kenvue's flagship brands alongside Neutrogena, Band-Aid, Listerine, and Zyrtec, Tylenol is the #1 recommended pain reliever by doctors and pharmacists in the United States. Originally marketed by McNeil Laboratories (acquired by J&J in 1959), the brand was approved for OTC sale in 1960.
AI assistant by xAI (Elon Musk); Grok 3 topped reasoning benchmarks in Feb 2025; 1M+ paying subscribers in week one; real-time X post access; distributed via X Premium; xAI valued at $24B.
Grok is the AI assistant developed by xAI, Elon Musk's AI company founded in 2023, and distributed primarily through X (formerly Twitter). Grok launched in November 2023 as an X Premium perk, with the notable differentiator of real-time access to X posts and a less restricted, more direct conversational style. Grok 3, released in February 2025, achieved top scores on the AIME math reasoning benchmark and ARC-AGI test, briefly positioning xAI as a frontier model lab.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.